Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Faster Aspart · 3 trials · 3 indications
Change from baseline (week 0) in HbA1c (%) as evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Change from baseline (week 0) in HbA1c (mmol/mol) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
pmol·h/L
Calculated based on insulin aspart measured in blood.
| Arm | Type | Description |
|---|---|---|
| Faster aspart | EXPERIMENTAL | 4 daily injections of faster aspart given with insulin degludec and with or without metformin |
| Insulin aspart | ACTIVE_COMPARATOR | 4 daily injections of insulin aspart given with insulin degludec and with or without metformin |
| NovoRapid® | ACTIVE_COMPARATOR | Subjects will receive 2 injections of a single dose of NovoRapid® at a predefined fixed dose level (0.2 U/kg body weight) for type 1 diabetes and (0.3 U/kg body weight) if subject has type 2 diabetes. |
| Faster aspart followed by insulin aspart (NovoRapid®) | EXPERIMENTAL | Participants will receive single dose of fast-acting insulin aspart followed by single dose of NovoRapid® on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days. |
| Insulin aspart (NovoRapid®) followed by faster aspart | EXPERIMENTAL | Participants will receive single dose of NovoRapid® followed by single dose of fast-acting insulin aspart on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days. |
| Name | Type | Description |
|---|---|---|
| Faster aspart | DRUG | Administered s.c. (subcutaneously, under the skin) for 16 weeks |
| Insulin aspart | DRUG | Administered s.c. (subcutaneously, under the skin) for 16 weeks |
| Insulin degludec | DRUG | Administered s.c. (subcutaneously, under the skin) for 16 weeks |
| Novo Rapid | DRUG | Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector. |
| Insulin aspart (NovoRapid®) | DRUG | An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal. |
Inclusion Criteria: * Male or female, age above or equal to 18 years at the time of signing informed consent * Diagnosed with Diabetes Mellitus, Type 1 (T1DM) at least or equal to 1 year prior to screening or diagnosed with Diabetes Mellitus, Type 2 (T2DM) at least or equal to 5 years prior to scre...
Faster Aspart is an investigational fast-acting insulin aspart being studied for the treatment of Diabetes Mellitus, Type 1 and Type 2 diabetes. It is developed by Novo Nordisk A/S and is currently in Phase 3 clinical development for these metabolic conditions.
Faster Aspart is developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with type 1 and type 2 diabetes.
Faster Aspart is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to determine its safety and effectiveness for treating diabetes.
Faster Aspart has been studied in several completed clinical trials, including NCT03407599, a Phase 1 trial in children, adolescents, and adults with type 1 diabetes, and NCT04588259, a Phase 3 trial comparing it to insulin aspart in Chinese people with diabetes. All trials are completed.
Faster Aspart is a fast-acting form of insulin aspart, designed to control blood sugar levels in people with diabetes. It works by replacing the insulin that the body normally produces, helping to regulate glucose metabolism and manage hyperglycemia in patients with type 1 and type 2 diabetes.